Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2022-08-15 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于实际控制人部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the release of pledge on shares held by the actual controller and related shareholders. It details the number of shares released from pledge, the proportion of shares pledged and released, and related shareholder information. There is no financial report, earnings data, or management discussion. The document is a specific announcement about share pledge status, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share capital status (release of pledged shares). The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is SHA with high confidence.
2022-08-15 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the release of pledged shares by the actual controller of the company, including detailed information about the shareholder, number of shares released from pledge, and related dates. It does not contain financial statements, management discussion, or audit information. It is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is a formal disclosure to the market about share pledge release.
2022-08-11 Chinese
江苏四环生物股份有限公司关于实际控制人持股变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding by the actual controller of the company, detailing the transfer of shares between related parties and the resulting shareholding percentages. It references regulatory compliance and confirms no change in the actual controller. There is no financial data, earnings information, or report publication mentioned. The content fits the definition of a Major Shareholding Notification, as it reports changes in significant share ownership levels.
2022-08-11 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the actual controller of the company, including detailed information about the number of shares pledged, the purpose of the pledge, and the financial status of the controlling party. It does not contain financial statements, audit results, or detailed financial performance data. It is a regulatory disclosure about share pledging, which fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit into more specific categories like capital changes or director dealings. The document length is 3534 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-08-05 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the release of pledge on shares held by the actual controller and other shareholders. It details the number of shares released from pledge, the proportion of shares pledged and released, and related information. There is no financial statement, earnings data, or report attached. The document is a specific announcement about share pledge status, which fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about share pledge changes and does not fit into other more specific categories like share issue or director dealings. The document length is short (1519 characters), and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-08-03 Chinese
江苏四环生物股份有限公司关于公司办公地址变更的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement about the change of the company's office address. It does not contain financial data, regulatory certifications, or detailed reports. It is a general regulatory announcement about company information update, which fits best under Regulatory Filings (RNS). The document length is only 403 characters, indicating it is a brief notice rather than a full report.
2022-08-03 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.